- Home
- CHN vs ALDX Comparison
CHN vs ALDX Comparison
Compare CHN & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- ALDX
- Stock Information
- Founded
- CHN 1992
- ALDX 2004
- Country
- CHN United States
- ALDX United States
- Employees
- CHN N/A
- ALDX N/A
- Industry
- CHN Investment Managers
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- CHN Finance
- ALDX Health Care
- Exchange
- CHN Nasdaq
- ALDX Nasdaq
- Market Cap
- CHN 128.4M
- ALDX 133.7M
- IPO Year
- CHN N/A
- ALDX 2014
- Fundamental
- Price
- CHN $12.25
- ALDX $2.15
- Analyst Decision
- CHN
- ALDX Strong Buy
- Analyst Count
- CHN 0
- ALDX 2
- Target Price
- CHN N/A
- ALDX $9.50
- AVG Volume (30 Days)
- CHN 31.8K
- ALDX 1.2M
- Earning Date
- CHN 01-01-0001
- ALDX 05-14-2025
- Dividend Yield
- CHN 0.19%
- ALDX N/A
- EPS Growth
- CHN N/A
- ALDX N/A
- EPS
- CHN N/A
- ALDX N/A
- Revenue
- CHN N/A
- ALDX N/A
- Revenue This Year
- CHN N/A
- ALDX N/A
- Revenue Next Year
- CHN N/A
- ALDX N/A
- P/E Ratio
- CHN N/A
- ALDX N/A
- Revenue Growth
- CHN N/A
- ALDX N/A
- 52 Week Low
- CHN $9.00
- ALDX $1.14
- 52 Week High
- CHN $12.98
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- CHN 47.57
- ALDX 38.93
- Support Level
- CHN $12.20
- ALDX $2.15
- Resistance Level
- CHN $12.57
- ALDX $2.30
- Average True Range (ATR)
- CHN 0.25
- ALDX 0.15
- MACD
- CHN -0.01
- ALDX 0.06
- Stochastic Oscillator
- CHN 20.48
- ALDX 37.93
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.